Two medication doses for early-stage lung cancer before surgery

Plain-English translation of NCT07269782 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a combination of two medications: HLX43 and . These are given as infusions (through an IV) before you have surgery to remove the cancer. The trial will compare two different doses of HLX43 to see which works best and is safest for people with early-stage lung cancer.

Currently, surgery alone is the main treatment for early-stage lung cancer, but cancer can come back. This trial is testing whether giving these medications before surgery might help destroy cancer cells and improve chances that the cancer won't return.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with stage II or IIIB non-small cell lung cancer that has not spread to distant sites
you are healthy enough to have surgery to remove the cancer, as confirmed by your surgeon
you have at least one measurable tumor visible on imaging scans
you are willing to provide a previous tumor tissue sample or undergo a biopsy for testing
you have good heart function and overall health status (ECOG score of 0 or 1)

You likely don't qualify if…

you have certain genetic mutations in your tumor (EGFR or ALK alterations) that make you a candidate for targeted therapy instead
you have had major surgery within the past 3 weeks
you are pregnant, breastfeeding, or unwilling to use contraception during the study
you have life expectancy of 3 months or less
you have received blood transfusions or certain growth factor treatments within 14 days before starting the study

What participation looks like

You would receive the two medications as IV infusions every 3 weeks for 3 or 4 cycles (about 9–12 weeks total). During this time, you would have regular clinic visits for monitoring and blood tests. After finishing the medications, if you remain eligible, you would undergo surgery to remove the cancer. The study team would follow your progress to see how well the treatment worked and check for any side effects.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(1 site)

China

Shanghai Pulmonary Hospital, Shanghai